Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
Lawrence Steinman,Edward Fox,Hans-Peter Hartung,Enrique Alvarez,Peiqing Qian,Sibyl Wray,Derrick Robertson,DeRen Huang,Krzysztof Selmaj,Daniel Wynn,Gary Cutter,Koby Mok,Yanzhi Hsu,Yihuan Xu,Michael S Weiss,Jenna A Bosco,Sean A Power,Lily Lee,Hari P Miskin,Bruce A C Cree,ULTIMATE I and ULTIMATE II Investigators,Sergey Kulesh,Yury Holets,Yuri Alekseenko,Halina Navumava,Vladimir Ponomarev,Aliaksandr Fedulau,Gleb Zabrodzets,Tea Mirosevic Zubonja,Spomenka Kidjemet Piskac,Mario Habek,Maka Mania,Nana Guldedava,Marina Janelidze,Ann Gauarashvili,Marina Kiziria,Roman Shakarishvili,Alexander Tsiskaridze,Andrzej Szczudlik,Ewa Motta,Adam Stepien,Jan Ilkowski,Andrzej Tutaj,Ewa Krzystanek,Jacek Zaborski,Janusz Zbrojkiewicz,Monika Adamczyk-Sowa,Andrey Yurchenko,Natalia Khachanova,Klara Bakhtiyarova,Igor Stolyarov,Stella Sivertseva,Gennady Mishin,Nikolay Dorogov,Denis Sazonov,Valentina Alifirova,Nadezhda Malkova,Larisa Volkova,Olga Patrusheva,Elena Arefyeva,Anna Belova,Denis Karpov,Natalya Totolyan,Vitalii Laskov,Gleb Makshakov,Larisa Lukyanchikova,Maria Zakharova,Dmitry Pokhabov,Natalia Maslova,Tatjana Boskovic-Matic,Jelena Drulovic,Tatjana Smiljkovic,Evica Dincic,Bonaventura Casanova,Francisco Gascon,Rafael Arroyo Gonzalez,Alfredo Rodriguez Antiguedad,Sergio Martinez Yelamos,Xavier Montalban,Tetiana Muratova,Serhiy Kareta,Valentyna Drobotenko,Larysa Kadina,Tetyana Nehrych,Kostiantyn Loganovskyi,Nataliya Lytvynenko,Volodymyr Smolanka,Marta Khavunka,Olena Tovazhnyanska,Valeriy Pashkovskyy,Ihor Pasiura,Iryna Ihnatenko,Yuliya Neryanova,Volodymyr Pryshchepa,Galyna Chmyr,Hanna Hrebeniuk,Sergii Moskovko,Svitlana Shkrobot,Alla Cherkez,Francisco Javier Carod-Artal,David Rog,Neil Robertson,Samuel Hunter,Amir Mazhari,Annette Okai,Richard Shubin,Benjamin Frishberg,Sharon Lynch,Kottil Rammohan,Evanthia Bernitsas,Le Hua,Mary Ann Picone,Emily Evans,Geoffrey Eubank,Mark Gudesblatt,Corey Ford
DOI: https://doi.org/10.1056/NEJMoa2201904
2022-08-25
Abstract:Background: The monoclonal antibody ublituximab enhances antibody-dependent cellular cytolysis and produces B-cell depletion. Ublituximab is being evaluated for the treatment of relapsing multiple sclerosis. Methods: In two identical, phase 3, double-blind, double-dummy trials (ULTIMATE I and II), participants with relapsing multiple sclerosis were randomly assigned in a 1:1 ratio to receive intravenous ublituximab (150 mg on day 1, followed by 450 mg on day 15 and at weeks 24, 48, and 72) and oral placebo or oral teriflunomide (14 mg once daily) and intravenous placebo. The primary end point was the annualized relapse rate. Secondary end points included the number of gadolinium-enhancing lesions on magnetic resonance imaging (MRI) by 96 weeks and worsening of disability. Results: A total of 549 participants were enrolled in the ULTIMATE I trial, and 545 were enrolled in the ULTIMATE II trial; the median follow-up was 95 weeks. In the ULTIMATE I trial, the annualized relapse rate was 0.08 with ublituximab and 0.19 with teriflunomide (rate ratio, 0.41; 95% confidence interval [CI], 0.27 to 0.62; P<0.001); in the ULTIMATE II trial, the annualized relapse rate was 0.09 and 0.18, respectively (rate ratio, 0.51; 95% CI, 0.33 to 0.78; P = 0.002). The mean number of gadolinium-enhancing lesions was 0.02 in the ublituximab group and 0.49 in the teriflunomide group (rate ratio, 0.03; 95% CI, 0.02 to 0.06; P<0.001) in the ULTIMATE I trial and 0.01 and 0.25, respectively (rate ratio, 0.04; 95% CI, 0.02 to 0.06; P<0.001), in the ULTIMATE II trial. In the pooled analysis of the two trials, 5.2% of the participants in the ublituximab group and 5.9% in the teriflunomide group had worsening of disability at 12 weeks (hazard ratio, 0.84; 95% CI, 0.50 to 1.41; P = 0.51). Infusion-related reactions occurred in 47.7% of the participants in the ublituximab group. Serious infections occurred in 5.0% in the ublituximab group and in 2.9% in the teriflunomide group. Conclusions: Among participants with relapsing multiple sclerosis, ublituximab resulted in lower annualized relapse rates and fewer brain lesions on MRI than teriflunomide over a period of 96 weeks but did not result in a significantly lower risk of worsening of disability. Ublituximab was associated with infusion-related reactions. (Funded by TG Therapeutics; ULTIMATE I and II ClinicalTrials.gov numbers, NCT03277261 and NCT03277248.).